• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Permanent leadership needed at FDA

Article

The future leadership of the Food and Drug Administration remains highly uncertain following the surprise resignation of Commissioner Lester Crawford in September.

WASHINGTON, D.C.-The future leadership of the Food and Drug Administration remains highly uncertain following the surprise resignation of Commissioner Lester Crawford in September.

The White House named Andrew von Eschenbach, director of the National Cancer Institute (NCI) at the National Institutes of Health (NIH), as acting FDA commissioner, but he got into trouble for trying to keep his NCI hat while taking the helm of FDA. Although he handed over day-to-day leadership of NCI to a deputy, that move failed to fully appease critics concerned about inherent conflicts of interest in advocating for speedy access to new cancer treatments while overseeing the safety and effectiveness of those therapies. HHS Secretary Michael Leavitt has indicated that von Eschenbach is not likely to get the top job at FDA on a permanent basis.

DAY-TO-DAY DEALINGS

But the uncertain atmosphere at FDA is making it difficult to move forward with important initiatives. A much-anticipated white paper on generic versions of costly biotech therapies, for example, has been delayed while the lawyers further examine policy and legal issues. FDA also plays a central role in ensuring public access to vaccines and therapies to guard against a possible flu epidemic, responsibilities that require strong leadership and ample resources.

All sides are looking to see if von Eschenbach bites the bullet and approves non-prescription use of Plan B, but as a close friend of President Bush, FDA's current leader may not be willing to do so.

Related Videos
Video 9 - "Denial of Coverage in Fertility Care"
Video 8 - "Risks of Miscarriage and Multiple Births Associated with Fertility Care"
Video 7 - "Fertility Preservation: Egg Freezing Versus Embryo Freezing"
Video 6 - "Family Building Costs, Barriers, and Dropout Rates Associated with Fertility Care"
Video 5 - "Closing Payer Gaps and Improving Fertility Care Access"
Video 4 - "Increasing Employer Coverage and Maximizing Fertility Benefits "
Video 5 - "Relevance of NUTURE Study Findings for Patients, Payers, Providers"
Video 3 - "Improving IVF Success Rates & Utilizing AI in Fertility Health Care"
Video 2 - "Holistic Fertility Management and Payer Collaboration"
Video 5 - "Relevance of NUTURE Study Findings for Patients, Payers, Providers"
Related Content
© 2024 MJH Life Sciences

All rights reserved.